Barriers to sustainable virologic suppression (VS) of HIV-infected adolescents and young adults include drug resistance mutations (DRMs) and limited treatment options, which may impact the outcome of second-line antiretroviral therapy (ART). We sequenced plasma viral RNA from 74 adolescents and young adults (16–24 years) failing first-line ART at Newlands Clinic, Zimbabwe between October 2015 and December 2016. We evaluated first-line nucleoside reverse transcriptase inhibitor (NRTI) susceptibility scores to first- and second-line regimens. Boosted protease inhibitor (bPI)-based ART was provided and viral load (VL) monitored for ≥48 weeks. Fisher's exact test was used to evaluate factors associated with VS on second-line regimens, defined as VL <1,000 copies/mL (VS1,000) or <50 copies/mL (VS50). The 74 participants on first-line ART had a median [interquartile range (IQR)] age of 18 (16–21) years and 42 (57%) were female. The mean (±standard deviation) duration on ART was 5.5 (±3.06) years and the median (IQR) log10 VL was 4.26 (3.78–4.83) copies/mL. After switching to a second-line PI regimen, 88% suppressed to <1,000 copies/mL and 76% to <50 copies/mL at ≥48 weeks. A new NRTI was associated with increased VS50 (p = .031). These 74 adolescents and young adults failing first-line ART demonstrated high levels (97%) of DRMs, despite enhanced adherence counseling. Switching to new NRTIs in second-line improved VS. With the widespread adoption of generic dolutegravir, lamivudine and tenofovir combinations in Africa, genotyping to determine NRTI susceptibility, may be warranted.
Get full access to this article
View all access options for this article.
References
1.
ICAP at Columbia University. Zimbabwe population-based HIV impact assessment ZIMPHIA 2015-2016. 2016. https://phia.i-cap.columbia.edu/wp-content/uploads/2016/11/ZIMBABWE-Factsheet.FIN_.pdf
2.
JaquetA, GaranetF, BalestreE, et al.: Antiretroviral treatment and quality of life in Africans living with HIV: 12-month follow-up in Burkina Faso. J Int AIDS Soc, 2013; 16:18867.
3.
MillsEJ, BakandaC, BirungiJ, et al.: Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: A cohort analysis from Uganda. Ann Intern Med, 2011; 155:209–216.
4.
World Health Organization. hiv-aids@who.intwww.who.int/hiv WHO/HIV/2017.58 Global AIDS Monitoring (UNAIDS/WHO/UNICEF) and WHO HIV Country Intelligence Tool, 2017. https://apps.who.int/iris/bitstream/handle/10665/ 259532/WHO-HIV-2017.58-eng.pdf
5.
SquiresKE, YoungB, DeJesusE, et al.: Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials, 2010; 11:69–79.
6.
WilkinsE, FisherM, BroganAJ, TalbirdSE, LaEM: Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV Med, 2016; 17:505–515.
7.
World Health Organization:Treat all: Policy adoption and implementation status in countries: Fact sheet. Geneva, Switzerland: World Health Organization, Department of HIV/AIDS.
8.
BonawitzR, BrennanAT, LongL, et al.: Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa. Trop Med Int Health, 2018; 23:650–660.
9.
HudelsonC, CluverL: Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low-and middle-income countries: A systematic review. AIDS Care, 2015; 27:805–816.
10.
InzauleSC, HamersRL, KityoC, de WitTFR, RouraM: Long-term antiretroviral treatment adherence in HIV-infected adolescents and adults in Uganda: A qualitative study. PLoS One, 2016; 11:e0167492.
11.
Nabukeera-BarungiN, ElyanuP, AsireB, et al.: Adherence to antiretroviral therapy and retention in care for adolescents living with HIV from 10 districts in Uganda. BMC Infect Dis, 2015; 15:520.
12.
BlancoJL, MontanerJS, MarconiVC, et al.: Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir+ emtricitabine/lamivudine+ efavirenz administered on a multiple tablet therapy. AIDS, 2014; 28:2531–2539.
13.
GanguliA, WangJ, GourleyDR: Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study. Res Soc Adm Pharm, 2012; 8:157–165.
14.
KennyJ, MulengaV, HoskinsS, ScholtenF, GibbDM: The needs for HIV treatment and care of children, adolescents, pregnant women and older people in low-income and middle-income countries. AIDS, 2012; 26:S105–S116.
15.
World Health Organization:. Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidance. Geneva, Switzerland: World Health Organization, 2018.
16.
ShamuT, ChimbeteteC, Shawarira–BoteS, MudzvitiT, LuthyR: Outcomes of an HIV cohort after a decade of comprehensive care at Newlands Clinic in Harare, Zimbabwe: TENART cohort. PLoS One, 2017; 12:e0186726.
17.
ManasaJ, DanaviahS, PillayS, et al.: An affordable HIV-1 drug resistance monitoring method for resource limited settings. J Vis Exp, 2014; [Epub ahead of print]; DOI: 10.3791/51242.
18.
KearseM, MoirR, WilsonA, et al.: Geneious basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics, 2012; 28:1647–1649.
19.
LiuTF, ShaferRW: Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis, 2006; 42:1608–1618.
20.
De OliveiraT, DeforcheK, CassolS, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics, 2005; 21:3797–3800.
21.
World Health Organization: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Available at http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf (2016), accessed May4, 2019.
22.
ShaferRW, SchapiroJM: HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev, 2008; 10:67.
23.
TangMW, LiuTF, ShaferRW: The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology, 2012; 55:98–101.
24.
OetteM, KaiserR, DäumerM, et al.: Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr, 2006; 41:573–581.
25.
Ministry of Health. Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in Zimbabwe. https://www.childrenandaids.org/sites/default/files/2017-05/Zimbabwe_HIV-Guidelines-Dec2013.pdf
26.
BoussariO, SubtilF, GenoliniC, et al.: Impact of variability in adherence to HIV antiretroviral therapy on the immunovirological response and mortality. BMC Med Res Methodol, 2015; 15:10.
27.
KonstantopoulosC, RibaudoH, RaglandK, BangsbergDR, LiJZ: Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia. Open Forum Infect Dis, 2015; 2:ofu119.
28.
AssemieMA, MuchieKF, AyeleTA: Incidence and predictors of loss to follow up among HIV-infected adults at Pawi General Hospital, northwest Ethiopia: Competing risk regression model. BMC Res Notes, 2018; 11:287.
29.
MulongeniP, HermansS, CaldwellJ, BekkerL-G, WoodR, KaplanR: HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. PLoS One, 2019; 14:e0210937.
30.
OkoronkwoI, OkekeU, ChinweubaA, IheanachoP: Nonadherence factors and sociodemographic characteristics of HIV-infected adults receiving antiretroviral therapy in Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. ISRN AIDS, 2013; 2013:843794.
31.
MakadzangeAT, Higgins-BiddleM, ChimukangaraB, et al.: Clinical, virologic, immunologic outcomes and emerging HIV drug resistance patterns in children and adolescents in public ART Care in Zimbabwe. PLoS One, 2015; 10:e0144057.
32.
Ministry of Health. MOHCC Zimbabwe OSDM 2017.pdf. 2017. Zimbabwe operational and service delivery manual & job aide. www.differentiatedcare.orghttp://www.differentiated care.org/Portals/0/adam/Content/JAOEkYYIREyKQ6R637v BmA/File/Zimbabwe_OSDM_webrevised_2017.pdf
33.
BoenderTS, KityoCM, BoermaRS, et al.: Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J Antimicrob Chemother, 2016; 71:2918–2927.
34.
CaoP, SuB, WuJ, et al.: Treatment outcomes and HIV drug resistance of patients switching to second-line regimens after long-term first-line antiretroviral therapy: An observational cohort study. Medicine (Baltimore), 2018; 97:e11463.
35.
EdessaD, SisayM, AsefaF: Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One, 2019; 14:e0220159.
36.
MurphyRA, SunpathH, CastillaC, et al.: Second-line antiretroviral therapy: Long-term outcomes in South Africa. J Acquir Immune Defic Syndr, 2012; 61:158.
37.
MusiimeV, KaudhaE, KayiwaJ, et al.: Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. AIDS Res Hum Retroviruses, 2013; 29:449–455.
38.
SchoffelenAF, WensingAM, TempelmanHA, GeelenSP, HoepelmanAI, BarthRE: Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa. PLoS One, 2013; 8:e58526.
39.
SigaloffKC, HamersRL, WallisCL, et al.: Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: Prospective cohort in Sub-Saharan Africa. J Infect Dis, 2012; 205:1739–1744.
40.
BrennerBG, CoutsinosD: The K65R mutation in HIV-1 reverse transcriptase: Genetic barriers, resistance profile and clinical implications. HIV Ther, 2009; 3:583–594.
41.
ChaplinB, ImadeG, OnwuamahC, et al.: Distinct pattern of thymidine analogue mutations with K65R in patients failing tenofovir-based antiretroviral therapy. AIDS Res Hum Retroviruses, 2018; 34:228–233.
42.
HolguínA, PaxinosE, HertogsK, WomacC, SorianoV: Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol, 2004; 31:215–220.
43.
SkhosanaL, SteegenK, BronzeM, et al.: High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One, 2015; 10:e0118145.
44.
SungkanuparphS, GrogerRK, OvertonET, FraserVJ, PowderlyWG: Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med, 2006; 7:437–441.
45.
WiddringtonJ, PayneB, MedhiM, ValappilM, SchmidML: The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect, 2011; 62:87–92.
46.
LeePK, KiefferTL, SilicianoRF, NettlesRE: HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother, 2006; 57:803–805.
47.
RyscavageP, KellyS, LiJZ, HarriganPR, TaiwoB: Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother, 2014; 58:3585–3598.
48.
KantersS, SociasME, PatonNI, et al.: Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: A systematic review and network meta-analysis. Lancet HIV, 2017; 4:e433–e441.
49.
FrentzD, BoucherCA, AsselM, et al.: Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One, 2010; 5:e11505.
50.
AndersonJA, JiangH, DingX, et al.: Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses, 2008; 24:685–694.
51.
Van LaethemK, De LucaA, AntinoriA, CingolaniA, PernaCF, VandammeA-M: A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1 infected patients. Antivir Ther, 2002; 7:123–130.
52.
BoydMA, MooreCL, MolinaJ-M, et al.: Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis. Lancet HIV, 2015; 2:e42–e51.
53.
HakimJG, ThompsonJ, KityoC, et al.: Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Lancet Infect Dis. 2018; 18:47–57.
54.
HillAM, VenterF: The unexpected success of NRTIs in second-line treatment. Lancet Infect Dis, 2018; 18:3–5.
55.
VardhanabhutiS, KatzensteinD, BartlettJ, KumarasamyN, WallisCL: Human immunodeficiency virus-1 sequence changes and drug resistance mutation among virologic failures of lopinavir/ritonavir monotherapy: AIDS clinical trials group protocol A5230. Open Forum Infect Dis, 2016; 3:ofw154.
56.
WallisCL, AgaE, RibaudoH, et al.: Drug susceptibility and resistance mutations after first-line failure in resource limited settings. Clin Infect Dis, 2014; 59:706–715.
57.
AbreuJC de, VazSN, NettoEM, BritesC: Virological suppression in children and adolescents is not influenced by genotyping, but depends on optimal adherence to antiretroviral therapy. Braz J Infect Dis, 2017; 21:219–225.
58.
BoermaRS, BunupuradahT, DowD, et al.: Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: Adolescents at high risk of failure. J Int AIDS Soc, 2017; 20:21930.
59.
LindseyJC, BoschRJ, RudyBJ, FlynnPM: Early patterns of adherence in adolescents initiating highly active antiretrovial therapy predict long-term adherence, virologic, and immunologic control. AIDS Patient Care STDs, 2009; 23:799–801.
60.
XuL, MunirK, KanabkaewC, Le CoeurS: Factors influencing antiretroviral treatment suboptimal adherence among perinatally HIV-infected adolescents in Thailand. PLoS One, 2017; 12:e0172392.
61.
DorwardJ, LessellsR, DrainPK, et al.: Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: Uncertainties and opportunities for implementation and research. Lancet HIV, 2018; 5:e400–e404.
62.
MeintjesG, MoorhouseMA, CarmonaS, et al.: Adult antiretroviral therapy guidelines 2017. South Afr J HIV Med, 2017; 18:776.
63.
VitoriaM, HillA, FordN, et al.: The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: What are the issues?. AIDS, 2018; 32:1551–1561.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
